Navigation Links
Revalesio Presents Update on the Development of RNS60 As A Therapeutic for Acute Heart Disease At the American Heart Association Scientific Sessions
Date:11/18/2013

TACOMA, Wash., Nov. 18, 2013 /PRNewswire/ -- Revalesio presented an update on the cellular protective effects of RNS60 in a pig model of acute myocardial infarction (AMI, heart attacks) at the 2013 American Heart Association Scientific Sessions in Dallas, Texas. As reported earlier this year at the American College of Cardiology meeting in San Francisco, RNS60 provided a 30% reduction in infarct size compared to normal saline in a model of AMI, the leading cause of death in the developed world. Despite many years of research and investigational studies, no drug has been developed to protect or limit the damage to the heart muscle caused by heart attacks. RNS60 was administered by intra-coronary injection and peripheral intravenous infusion. In this update, Revalesio researchers looked at intracellular pathways involved in cell death and survival and found that RNS60 treatment significantly modulates the level of a protein called HSP90, one of the general stress response proteins found in all cell types.

"After the initial observation of the significant improvement in infarct size achieved by RNS60 treatment, we are now diving deep into the mechanism of action behind this effect," said Revalesio's Andreas Kalmes, Ph.D., who presented the data. "The data presented at this meeting show that RNS60 inhibits apoptosis, or programmed cell death, in heart muscle cells, and provides an important clue that RNS60 affects the general stress response of cells. Apoptosis has been recognized as an important driver in heart muscle damage following a heart attack, and as a promising target to improve outcome for patients. These findings further validate our approach to develop RNS60 as a therapeutic for heart attack patients."

The reduction in infarct size, suppression of programmed cell death as a consequence of a heart attack, and the excellent safety profile provides strong rationale for the development of RNS60 as a novel treatment option for patients with AMI.

About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines resulting in decreased inflammation and cell death. RNS60 contains CSN that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation
Revalesio is a pioneering clinical stage biotechnology company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuroinflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

Press Contact:
Jesse Thomas
253-926-5567
Email

Read more news from Revalesio Corporation


'/>"/>
SOURCE Revalesio
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Revalesio Initiates Phase IIa Study of RNS60 in Multiple Sclerosis at University Hospital Zurich
2. Revalesio Presents Data Showing RNS60 Alters Disease Progression in Animal Model of Alzheimers Disease Through the PI3k-Akt Pathway
3. Pi2 Solutions Presents on Pharmacovigilance Literature Screening at Major European Risk Management Meeting
4. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
5. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
6. Rheumatology Network Presents Latest Advances Against Baffling Inflammatory Diseases From Major Rheumatology Conference
7. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
8. Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia
9. Healthcare Trust of America CEO Scott D. Peters Presents at the Arizona State University Real Estate Council
10. Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
11. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2019)... ... June 14, 2019 , ... ... forecasting and analytics platform that helps Life Sciences Manufacturers accurately project their ... Life Sciences business leaders: accurate, automated forecasting of rebates and discounts and ...
(Date:6/13/2019)... ... June 13, 2019 , ... IPVideo Corporation ... visual weapons detection systems, is proud to announce its verified integration with its ... verified technology partner IPVideo’s award-winning HALO sensor is now available on the Milestone ...
(Date:6/13/2019)... ... June 13, 2019 , ... Online laser therapy ... professionals and the public about non-invasive photobiomodulation (PBM) therapy to relieve pain. LTU ... help commemorate the milestone. , Also known as low-level laser therapy ...
Breaking Medicine Technology:
(Date:6/16/2019)... ... , ... Convoy of Hope continues to celebrate its 25th anniversary. Since its ... around the world. To date, Convoy has worked with more than 46,000 partners to ... possible without the dedication and generosity of churches, organizations, and individuals who believe in ...
(Date:6/14/2019)... N.J. (PRWEB) , ... June 14, 2019 , ... FL Top Docs is proud to present the following recently reviewed and approved providers for May ... Dietrick , BREAST SURGERY, Dr. Debbie Berlin ... Khan , Dr. Christopher J. Pastore , Dr. Yamilet Tirado ...
(Date:6/13/2019)... PETERSBURG, Fla. (PRWEB) , ... June 13, 2019 ... ... and research company today announced that it has signed a memorandum of understanding ... (API) for its drug product MMJ-001 and MMJ-002. , MMJ BioPharma Cultivation will ...
(Date:6/13/2019)... , ... June 13, 2019 , ... In Partnership with ... dental services for low-income, underinsured individuals at its Mesquite, TX office on July 13th. ... fillings, cleanings and extractions . For more information, please visit the ...
(Date:6/13/2019)... ... June 13, 2019 , ... The ... present the second annual Women|Future Conference and the advisory board that ... better position themselves and their organizations in tomorrow's marketplace. , The mission of ...
Breaking Medicine News(10 mins):